Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), B cell aplasia and hypogammaglobulinemia are common toxicities p...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Cancer J
Main Authors: Wudhikarn, Kitsada, Palomba, M. Lia, Pennisi, Martina, Garcia-Recio, Marta, Flynn, Jessica R., Devlin, Sean M., Afuye, Aishat, Silverberg, Mari Lynne, Maloy, Molly A., Shah, Gunjan L., Scordo, Michael, Dahi, Parastoo B., Sauter, Craig S., Batlevi, Connie L., Santomasso, Bianca D., Mead, Elena, Seo, Susan K., Perales, Miguel-Angel
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7405315/
https://ncbi.nlm.nih.gov/pubmed/32759935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00346-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares